|
|||||
|
|
Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report |
|
| Affiliation: | 1. Stanford University School of Medicine, Stanford, CA;2. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA;3. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA;4. Department of Pathology, Stanford University School of Medicine, Stanford, CA |
| Abstract: | |
| Keywords: | Alectinib Driver mutation Osimertinib Second NSCLC Targeted therapy |
| 本文献已被 ScienceDirect 等数据库收录！ | |